This article is policy analysis and general information only. It is not clinical advice. Antimicrobial prescribing, stewardship, and surveillance policy in Australia evolve rapidly; always check current guidance from the Therapeutic Goods Administration (TGA), the Australian Commission on Safety and Quality in Health Care (ACSQHC), and Therapeutic Guidelines before relying on any specific point.

Antimicrobial Resistance in Australia: Stewardship, Surveillance, and the Path Through 2030

Antimicrobial resistance (AMR) is one of the few public health threats that is simultaneously urgent, gradual, and almost invisible at the bedside. A clinician in a Brisbane emergency department who prescribes a third-generation cephalosporin for a routine urinary tract infection is not consciously contributing to a future in which that same drug no longer works — yet, in aggregate, every avoidable prescription nudges the resistance curve upward. The same logic applies in a dairy operation in Gippsland, an aquaculture pen in Tasmania, and a dental surgery in Western Sydney. AMR is a slow, collective harm produced by millions of individually rational decisions, and that is precisely what makes it so hard to govern.

Australia has been engaged in formal AMR policy work for more than a decade. The current framework is anchored by the Australian Government National AMR Strategy, a joint Department of Health and Department of Agriculture initiative covering 2020 through 2030, with a One Health framing that explicitly couples human, animal, and environmental antibiotic use. The implementation infrastructure — surveillance through AURA, stewardship through the ACSQHC, prescribing influence through the PBS and Therapeutic Guidelines, animal-use oversight through the Australian Pesticides and Veterinary Medicines Authority (APVMA), and ongoing professional standards work through the Pharmacy Board and the colleges — is more developed than in most comparable economies.

It is also, by the Strategy's own midpoint review, falling short of its targets. This article walks through where the National AMR Strategy actually sits in 2026, what AURA is telling us about prescribing and resistance, where the remaining policy gaps are, and what reform priorities are likely to shape the second half of the Strategy through 2030.

1. What AMR is, and why "stewardship" is the policy lever

Antimicrobial resistance is the evolutionary process by which bacteria, fungi, viruses, and parasites acquire the ability to survive exposure to drugs that previously killed or inhibited them. In the policy and clinical literature, the most pressing subset is antibacterial resistance — the loss of effectiveness in the antibiotic classes that underpin modern surgical, oncological, transplant, neonatal, and intensive care medicine.

The mechanism is straightforward. Antibiotic exposure selects for resistant organisms in any population of bacteria — in a patient's gut, on a hospital surface, in a piggery effluent pond, or in a river downstream of a wastewater treatment plant. The more antibiotic is used, the stronger the selection pressure, and the more rapidly resistance genes spread through horizontal gene transfer between species. There is no realistic scenario in which resistance is eliminated; the policy question is how fast it grows, and whether new drug development keeps pace.

The dominant policy response globally — and the one Australia has built its strategy around — is antimicrobial stewardship (AMS). Stewardship is the deliberate, institutional management of how antibiotics are prescribed, supplied, used, and disposed of, with the dual goals of preserving effectiveness and improving patient outcomes. It is not, despite occasional public framing, a campaign against antibiotics; it is a campaign for using the right antibiotic, at the right dose, for the right duration, only when one is genuinely required.

2. The National AMR Strategy 2020-2030: structure and midpoint reality

The National AMR Strategy sets seven priority areas, of which four matter most for policy reform:

1. Stronger surveillance of antimicrobial use and resistance across human and animal health.
2. Effective infection prevention and control across health, aged care, and agricultural settings.
3. Stewardship practice that minimises inappropriate prescribing and supply.
4. Sustained investment in research, including diagnostics and the antibiotic pipeline.

The Strategy's design is good. Its midpoint experience has been mixed. Hospital stewardship is, by international standards, mature: AMS programs are an accreditation requirement under the National Safety and Quality Health Service (NSQHS) Standards, all public and most private acute hospitals run multidisciplinary AMS teams, and reporting through AURA gives a credible national picture. Aged care stewardship has improved from a very low base. Primary care stewardship, animal-use stewardship, and pipeline policy remain the hard problems — and they are precisely the areas where the Strategy's second half will be judged.

3. AURA: what the surveillance is actually showing

The AURA reports — ACSQHC provide Australia's integrated national picture of antimicrobial use and resistance across hospital, community, and aged care settings. Several findings have remained stubbornly consistent across successive AURA cycles.

First, Australia is a relatively high antibiotic-using country. Per-capita community antibiotic use sits above the OECD median and well above countries such as the Netherlands and Sweden, despite repeated stewardship campaigns. The bulk of community prescribing is concentrated in upper respiratory tract infections (URTIs), dental indications, and uncomplicated urinary infections — the same three categories where guideline-discordant prescribing rates are highest.

Second, resistance trends in priority organisms are heading in the wrong direction. Fluoroquinolone resistance in Escherichia coli from community urinary infections has climbed steadily. Carbapenemase-producing Enterobacterales (CPE) detections have moved from rare to routinely reported, with hospital outbreaks documented in multiple jurisdictions. Resistance in Neisseria gonorrhoeae — driven by very different exposure pathways — has narrowed the available treatment options to ceftriaxone-based regimens, with a small but increasing number of reduced-susceptibility isolates.

Third, the human-animal interface continues to matter. AURA's One Health reporting has surfaced overlapping resistance signals — particularly for extended-spectrum beta-lactamase (ESBL)-producing organisms — that cannot be cleanly assigned to either sector and that argue strongly against treating human and animal stewardship as separate problems.

4. Primary care: where the volume sits

Roughly four-fifths of human antibiotic use in Australia happens outside hospitals, and the lion's share of that sits in general practice and dental practice. The policy problem is not a small number of high-volume prescribers — it is a large number of clinicians each making a handful of marginal calls per week, in the time-pressured, diagnostic-uncertainty environment of routine primary care.

Three prescribing patterns are repeatedly flagged in AURA and in independent audits:

• URTIs. A large majority of acute sore throat, otitis media, sinusitis, and bronchitis presentations in Australian general practice still result in an antibiotic prescription, despite guidelines that recommend no antibiotic, or delayed prescribing, in most cases. This pattern has been stubbornly resistant to repeated educational campaigns.
• Dental prescribing. Australian dentists prescribe antibiotics at higher rates than peers in several comparable systems, often for indications — pulpitis, post-extraction prophylaxis in healthy patients — where guidelines do not support their use. Dental antibiotic prescribing is a quietly significant contributor to total community use.
• Paediatric prescribing. Children under five are prescribed antibiotics at high rates, predominantly for viral URTIs. Parental expectation, diagnostic uncertainty in young children, and consultation length all interact here.

The intervention toolkit is well-known: structured audit and feedback to individual prescribers, mandatory delayed-prescription pathways for low-severity presentations, integration of stewardship prompts into electronic prescribing software, public reporting at the practice level, and embedding stewardship in continuing professional development requirements. The implementation gap, not the evidence gap, is the binding constraint.

The broader primary care workforce environment matters too. Shorter consultations and higher caseloads correlate with higher antibiotic prescribing — stewardship is partly a workforce policy question, as canvassed in our rural and remote health access policy analysis.

5. Hospital antimicrobial stewardship: the mature end of the system

In Australian acute hospitals, AMS is now structurally embedded. Under the NSQHS Standards, every accredited hospital must operate a formal AMS program, with documented governance, multidisciplinary leadership (typically an infectious diseases physician, an AMS pharmacist, and a microbiologist), prescribing audits, restricted antimicrobial approval pathways, and reporting into the National Antimicrobial Prescribing Survey (NAPS).

The results are visible. Hospital-onset Clostridioides difficile infection has trended downward over the past decade. Use of last-line agents — carbapenems, polymyxins, and newer beta-lactam/beta-lactamase inhibitor combinations — is closely tracked and generally requires AMS approval. Surgical prophylaxis durations have shortened in line with evidence.

The remaining hospital-side issues are concentrated in three areas: smaller rural and remote hospitals where AMS staffing is thin, private hospitals with variable AMS maturity, and the transitions of care between hospital and primary care, where discharge antibiotic decisions are often inherited rather than reviewed.

6. The WHO AWaRe classification and how Australia uses it

The WHO AWaRe classification groups antibiotics into three categories — Access, Watch, and Reserve — based on their spectrum, resistance potential, and clinical role.

• Access antibiotics (e.g. amoxicillin, doxycycline, nitrofurantoin) are narrow-spectrum, first-line agents that should make up the majority of community prescribing.
• Watch antibiotics (e.g. fluoroquinolones, macrolides, third-generation cephalosporins) have higher resistance selection potential and should be used more selectively.
• Reserve antibiotics (e.g. linezolid, ceftazidime-avibactam, colistin in humans) are last-line agents for confirmed multidrug-resistant infections.

WHO's global target is for Access antibiotics to make up at least 60% of total antibiotic consumption. Australia consistently sits in roughly the right range at the national level, but with significant variation by geography, indication, and prescriber group. AURA increasingly reports against AWaRe categories, and AWaRe is being progressively integrated into Therapeutic Guidelines and into stewardship dashboards in larger health services. Aligning PBS prescribing data, hospital procurement data, and AURA reporting against AWaRe is a quiet but important piece of policy plumbing through to 2030.

7. Animal-use antibiotics, APVMA, and the colistin question

The animal side of the Australian AMR picture is regulated primarily by the APVMA, which approves and conditions the registration of veterinary antimicrobials. Australia's record here is genuinely better than many comparable countries on a few specific dimensions. Fluoroquinolones have never been approved for use in Australian food-producing animals — a foresighted decision that has likely preserved the clinical utility of ciprofloxacin and related agents in human medicine. Colistin, classified by the WHO as a critically important antimicrobial for human medicine, is also tightly restricted in food-producing animal use.

The harder debates sit in three areas:

• Growth-promotant use and prophylactic mass medication. Although Australia has moved away from antibiotic growth promoters, in-feed and in-water prophylactic use for groups of animals — rather than treatment of identified infection — remains a feature of intensive livestock production. This is where the largest volume reductions are still possible.
• Aquaculture. Antibiotic use in finfish aquaculture, particularly in salmon production, has attracted increasing policy attention as the sector has grown. Environmental dispersion of antibiotic residues and resistance genes through marine pen systems is a distinctively One Health problem.
• Companion animals. Veterinary prescribing for dogs and cats — particularly broad-spectrum agents — is less tightly governed than food-animal use, and the resistance signals coming through small-animal practice (ESBL E. coli, methicillin-resistant Staphylococcus pseudintermedius) are not trivial.

Strengthening APVMA-led surveillance of animal antibiotic sales, integrating it more tightly with AURA, and tightening conditions on critically important antimicrobials are all on the second-half agenda for the National AMR Strategy.

8. Diagnostic stewardship: the missing leg

If stewardship is about right drug, right patient, right duration, then diagnostics are how clinicians actually know what is right. Diagnostic stewardship — making sure tests are ordered appropriately, results returned quickly, and decisions actually changed by them — is the area where Australian policy has lagged behind clinical opportunity.

The technologies that matter are already in use elsewhere. Rapid point-of-care (POC) tests for group A Streptococcus in sore throat, multiplex respiratory PCR panels in general practice during winter, urinary dipstick-plus-culture pathways with structured follow-up, and procalcitonin-guided antibiotic decisions in selected hospital and aged-care contexts can each meaningfully reduce unnecessary prescribing when paired with prescriber education and an aligned reimbursement structure.

The binding constraint in Australia is almost never clinical evidence. It is whether the MBS funds the test, whether the workflow in a 15-minute consultation actually supports its use, and whether the result is integrated into the prescribing software. Diagnostic stewardship sits squarely in MBS reform territory and overlaps with the broader argument made in our preventive health funding policy in Australia analysis: under-investment upstream produces overuse downstream.

9. The antibiotic pipeline crisis and push/pull funding

Even perfect stewardship would not, on its own, solve AMR. Resistance evolves; new drugs are needed. And the global pipeline of novel antibiotics is, by widely accepted measures, dangerously thin. Several major pharmaceutical companies have exited antibiotic development entirely. Small biotech firms that have brought new agents to market in recent years have repeatedly entered bankruptcy or sold their pipelines at a loss, because successful stewardship — restricting use of new agents to preserve their effectiveness — also restricts the revenue that conventional pharmaceutical economics requires.

The policy response is built around two mechanisms:

• Push funding subsidises the front end of development — basic discovery, preclinical and early clinical research, public-private partnerships, and academic-industry consortia such as CARB-X and the AMR Action Fund.
• Pull funding rewards successful market entry independently of sales volume. The most prominent model is the UK NHS's subscription-style payment, under which an approved antibiotic earns a fixed annual fee for guaranteed availability, with prescribing volume managed entirely by stewardship.

Australia has been a participant in international push-funding mechanisms but does not, as of 2026, operate a domestic pull-funding model. A delinked-payment pilot for nationally significant antimicrobials is one of the more substantive structural reforms that could come out of the National AMR Strategy's second half, and it overlaps with the broader regulatory economics issues canvassed in our TGA reform priorities for 2027 piece.

10. Pharmacy-led stewardship and expanded scope

Pharmacists sit in three structurally important AMR positions — dispensing antibiotics in community pharmacy, leading hospital AMS programs, and, increasingly, prescribing directly under expanded-scope arrangements in some jurisdictions.

That last point matters. As more states roll out community pharmacist prescribing for limited indications — UTIs, oral contraception, minor skin infections, certain travel-medicine and respiratory conditions — the stewardship implications cut both ways. Done well, with structured protocols, integrated diagnostics, mandatory reporting, and clear referral criteria, pharmacist prescribing can reduce inappropriate antibiotic use, particularly for UTIs where dipstick-plus-protocol pathways outperform telephone-triage prescribing. Done poorly, without those guardrails, it risks adding a new volume of community prescribing that escapes existing AMS infrastructure.

The reform challenge — that pharmacist prescribing must be designed around stewardship rather than retrofitted into it — is the same theme developed in our pharmacy scope of practice debate analysis.

11. One Health, international coordination, and the path through 2030

AMR is the canonical One Health problem. Resistance genes move between humans, animals, food, water, and the broader environment, and no single sector can solve it alone. Australia's participation in the WHO Global Action Plan on AMR, the FAO/WOAH/UNEP/WHO Quadripartite governance arrangements, and regional mechanisms in the Indo-Pacific gives it both an obligation and a comparative advantage — particularly in supporting AMR surveillance capacity in lower-resource neighbours where antibiotic supply chains are less regulated.

The reform priorities most likely to define the second half of the National AMR Strategy are reasonably clear:

• A funded primary care AMS program with structured prescriber feedback, mandatory delayed-prescription pathways for low-severity URTIs, and embedded electronic decision support.
• MBS-funded POC diagnostics, beginning with strep throat, urinary infections, and respiratory viral panels.
• A domestic pull-funding pilot for new antimicrobials, modelled on the UK subscription approach, paired with reciprocal regulatory recognition.
• Tighter APVMA conditions on group-medication antimicrobial use in livestock and aquaculture, with stronger integrated surveillance.
• Continued accreditation-linked AMS in aged care, private hospitals, and dental practice.
• Expanded-scope pharmacist prescribing redesigned with stewardship as a core, not optional, feature.

None of these reforms are technically difficult. The technical evidence base is mature; the bottleneck is governance and funding. AMR is the kind of slow, distributed, intersectoral problem at which Australian federal-state health policy has historically struggled — but the National AMR Strategy is, on its own terms, the right structure to address it. Whether the second half delivers will depend on whether implementation is funded at the scale the threat warrants, and whether human, animal, and environmental health policy can finally be governed as the single system the bacteria already know it to be.

References and further reading

• Australian Government National AMR Strategy — joint Department of Health and Department of Agriculture, Fisheries and Forestry national strategy 2020-2030.
• AURA reports — ACSQHC — Antimicrobial Use and Resistance in Australia surveillance system.
• WHO AWaRe classification — World Health Organization 2021 AWaRe classification of antibiotics.